XML 24 R11.htm IDEA: XBRL DOCUMENT
v3.20.2

Goodwill and Other Intangible Assets | 9 Months Ended
--- | ---
Oct. 02, 2020
Goodwill and Intangible Assets Disclosure [Abstract] |
Goodwill and Other Intangible Assets | GOODWILL AND OTHER INTANGIBLE ASSETS The following is a rollforward of the Company’s goodwill ($ in millions):
Balance, December 31, 2019 | $ | 22,712.5 |
Attributable to 2020 acquisitions | 10,301.4 |
Attributable to 2020 divestitures | (180.5) |
Adjustments due to finalization of purchase price allocations | (3.0) |
Foreign currency translation and other | 1,439.3 |
Balance, October 2, 2020 | $ | 34,269.7 |
The carrying value of goodwill by segment is summarized as follows ($ in millions):
| October 2, 2020 |  | December 31, 2019
Life Sciences | $ | 24,866.5 |  |  | $ | 13,471.8 |
Diagnostics | 6,951.6 |  |  | 6,901.2 |
Environmental & Applied Solutions | 2,451.6 |  |  | 2,339.5 |
Total | $ | 34,269.7 |  |  | $ | 22,712.5 |
The increase in the goodwill balance of the Life Sciences segment in the nine-month period ended October 2, 2020 is a result of the Cytiva Acquisition. Measurement period adjustments since acquisition decreased the goodwill recognized for the Cytiva Acquisition by approximately $1.3 billion, as the initial allocation of the purchase price was adjusted to allocate additional purchase price to technology, customer relationships and trade names partially offset by related deferred tax liabilities. Refer to Note 3 for more detail. The Company has not identified any “triggering” events which indicate an impairment of goodwill in 2020. Finite-lived intangible assets are amortized over their legal or estimated useful life. The following summarizes the gross carrying value and accumulated amortization for each major category of intangible assets ($ in millions):
| October 2, 2020 |  |  |  | December 31, 2019 |  |
| Gross Carrying Amount |  | Accumulated Amortization |  | Gross Carrying Amount |  | Accumulated Amortization
Finite-lived intangibles: |  |  |  |  |  |  |
Patents and technology | $ | 11,944.3 |  |  | $ | (1,329.4) |  |  | $ | 2,712.7 |  |  | $ | (934.1) |
Customer relationships, trade names and other intangibles | 8,942.3 |  |  | (3,013.3) |  |  | 6,367.4 |  |  | (2,612.3) |
Total finite-lived intangibles | 20,886.6 |  |  | (4,342.7) |  |  | 9,080.1 |  |  | (3,546.4) |
Indefinite-lived intangibles: |  |  |  |  |  |  |
Trademarks and trade names | 4,310.3 |  |  | — |  |  | 4,216.0 |  |  | — |
Total intangibles | $ | 25,196.9 |  |  | $ | (4,342.7) |  |  | $ | 13,296.1 |  |  | $ | (3,546.4) |
During the nine-month period ended October 2, 2020, the Company acquired finite-lived intangible assets, consisting primarily of developed technology, customer relationships and trade names, with a weighted average life of 17 years primarily as a result of the Cytiva Acquisition. Refer to Note 3 for additional information on the intangible assets acquired. The Company identified impairment triggers during the first and third quarters of 2020 which resulted in the impairment of certain long-lived assets, including trade names and other intangible assets. The Company recorded impairment charges totaling $14 million and $22 million in the three and nine-month periods ended October 2, 2020, respectively, related to these long-lived assets.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration